The twin-targeting CAR T-cell remedy KITE-363 confirmed constructive response charges and manageable unwanted effects in relapsed or refractory B-cell lymphoma.
Amongst sufferers with relapsed/refractory B-cell lymphoma, the anti-CD19/CD20 CAR T-cell remedy KITE-363 showcased excessive response charges with a manageable security profile, in response to outcomes from a first-in-human part 1 examine offered through the 2025 ASCO Annual Assembly.
Security knowledge indicated that no dose-limiting toxicities had been reported in part 1a. Grade 3 (extreme) or increased unwanted effects had been skilled by 2 sufferers who obtained the agent at dose degree 1 (DL1; 3 sufferers), which was 0.5 x 10⁶ CAR T cells/kg. Grade 3 or increased unwanted effects had been reported in six sufferers who obtained dose degree 2 (DL2; 8 sufferers), which was 1 x 10⁶ CAR T cells/kg. In those that obtained dose degree 3 (DL3; 26 sufferers), which was 2 x 10⁶ CAR T cells/kg, the most typical grade 3 or increased unwanted effects included decreased white blood cell rely (11 sufferers), neutropenia (8 sufferers) and decreased neutrophil rely (11 sufferers).
Furthermore, one grade 3 case of cytokine launch syndrome (CRS) was reported in a affected person with nodular lymphocyte-predominant Hodgkin lymphoma; the period of the occasion was someday. Three grade 3 immune effector cell–related neurotoxicity syndrome (ICANS) occasions had been noticed: one within the DL2 group, which had a period of 4 days, and two within the DL3 group, which had durations of 1 and two days, respectively. Notably, no grade 3 or increased CRS or ICANS occasions had been noticed in these with major refractory giant B-cell lymphoma who obtained the CAR T-cell remedy at DL3 (15 sufferers).
In sufferers with out prior publicity to CAR T-cell remedy who obtained KITE-363 at DL3 (23 sufferers), the target response charge was 87%, and this was comprised of a whole response charge of 78% and a partial response charge of 9%. 4 % of sufferers had secure illness and 9% had progressive illness. Inside this group, these with giant B-cell lymphoma who had beforehand obtained at the least two traces of remedy (seven sufferers) skilled an goal response charge and full response charge of 100% every. These with major refractory giant B-cell lymphoma (15 sufferers) skilled an goal response charge of 80% and a whole response charge of 67%. Of the three sufferers who had prior CAR T publicity and obtained DL3, one achieved a whole response.
Amongst those that obtained KITE-363 at DL1 and DL2 (11 sufferers), the target response charge was 64%, with a whole response charge of 36% and a partial response charge of 27%. 9 % skilled secure illness and 27% had progressive illness.
“These outcomes assist KITE-363 as a promising therapeutic method for sufferers with relapsed/refractory B-cell lymphoma together with these with extremely refractory giant B-cell lymphoma,” Saurabh Dahiya, MD, FACP, an affiliate professor of medication at Stanford College Faculty of Drugs in Stanford, California, stated in a presentation of the information.
Retaining Up With KITE-363 and Its Analysis in R/R B-Cell Lymphoma
The bicistronic, lentiviral-encoded autologous CAR T-cell remedy, KITE-363, is twin focused. The anti-CD19 and anti-CD20 CAR possess a CD28 costimulatory area and a 4-1BB costimulatory area, respectively. “Twin focusing on has the potential to handle tumor heterogeneity and enhance the sturdiness of responses by stopping CD19-negative relapses,” Dahiya famous.
The open-label, multicenter, part 1 examine utilized a 3 plus 3 examine design. It was comprised of a part 1a dose-escalation portion and a part 1b dose-expansion portion. For part 1a, sufferers had histologically confirmed relapsed/refractory B-cell lymphoma by World Well being Group standards following greater than two traces of remedy or second-line major refractory illness. Section 1b solely enrolled sufferers with relapsed/refractory giant B-cell lymphoma, which included these with second-line major refractory illness. All sufferers had been at the least 18 years of age and had an ECOG efficiency standing of 0 or 1.
They had been excluded if that they had Richter transformation, central nervous system involvement of lymphoma, lively an infection, or a central nervous system dysfunction of medical significance. These with clinically vital autoimmune or cardiac illness had been additionally excluded.
The first finish factors for part 1a and part 1b had been incidence of dose-limiting toxicities and goal response charge, respectively. Secondary finish factors included full response charge, period of response, progression-free survival, time to subsequent therapy, general survival, security, and ranges of CAR T cells and cytokines within the blood.
After screening, sufferers had been enrolled and underwent leukapheresis. This was adopted by optionally available bridging remedy, which was comprised of corticosteroids with or with out native radiation remedy per investigator discretion. From day –5 to –three, sufferers obtained lymphodepleting chemotherapy comprised of cyclophosphamide at 300 milligrams per sq. meter (mg/m²) each day and fludarabine at 30 mg/m² each day for 3 days. On day 0, sufferers had been infused with KITE-363 at one of many three dose ranges. For DL3, the median time from leukapheresis to infusion with the CAR T-cell remedy was 27 days. The primary post-infusion response evaluation was performed on day 28.
A complete of 41 sufferers had been enrolled and underwent leukapheresis. Three of those sufferers weren’t handled, and the remaining 38 went on to obtain lymphodepleting chemotherapy. As a result of one affected person didn’t meet protocol-required eligibility to obtain KITE-363, a complete of 37 sufferers obtained the CAR T-cell remedy.
On the knowledge cutoff date of March 18, 2025, the median follow-up in those that obtained therapy (37 sufferers) was 12.4 months. The median follow-up for these within the DL3 group was 11.1 months.
The median age for all handled sufferers was 62 years, with 46% aged 65 years or older and 11% aged 75 years or older. Within the DL3 group, the median age was 60.5 years, with 42% aged 65 years or older and 12% aged 75 years or older. Greater than half of sufferers had been male (65%), most had been White (78%), most weren’t Hispanic or Latino (86%) and had an ECOG efficiency standing of 1 (60%). Furthermore, 73% of all handled sufferers had stage III or 4 illness at examine entry, as did 65% of these within the DL3 group.
In all handled sufferers, the most typical histologic subtype was giant B-cell lymphoma (92%), adopted by indolent non-Hodgkin lymphoma (5%) and nodular lymphocyte-predominant Hodgkin lymphoma (3%). Within the DL3 group, the most typical histologic subtype was additionally giant B-cell lymphoma (96%), adopted by nodular lymphocyte-predominant Hodgkin lymphoma (4%). Nineteen % of all handled sufferers and 15% of these within the DL3 group had cumbersome illness, which was outlined as at the least 7.5 centimeters. Dahiya famous that sufferers had tumors that had been constructive for CD19 and/or CD20, with most sufferers (78%) having tumors that had been constructive for each. 13 % of sufferers had tumors that had been constructive for 1 antigen.
In all handled sufferers, 46% had been major refractory and 54% had obtained two or extra prior regimens. Nineteen % obtained prior CD19-targeted CAR T-cell remedy, 14% beforehand underwent autologous stem cell transplant and 57% had obtained bridging remedy. Within the DL3 group, 58% had been major refractory and 42% had obtained at the least two prior traces of therapy. Within the 15 sufferers who had been major refractory, 4 skilled partial responses as finest response to frontline therapy and 11 skilled progressive illness. Prior CD19-targeted CAR T-cell remedy and prior autologous stem cell transplant had been obtained by 12% and 15% of sufferers, respectively. Fifty-eight % of sufferers on this group obtained bridging remedy.
Further Efficacy Knowledge
The median period of full response, outlined as period of response of all sufferers who achieved a whole response as finest response, was not reached. The period of full response charge at 6 months was 71.4%. “Knowledge past 6 months is closely impacted by censoring,” Dahiya famous. “Longer follow-up is required.” 9 of the 37 sufferers who obtained therapy died; 8 died as a consequence of progressive illness.
Security Highlight
Amongst those that obtained the CAR T-cell remedy at DL3, all sufferers skilled any-grade unwanted effects. Eighty-one % of those results had been grade 3 or increased. Any-grade and grade 3 or increased critical unwanted effects had been reported in 54% and 38% of sufferers, respectively. Any-grade cardiac problems had been skilled by 35% of sufferers; 4% had been grade 3 or increased. Any-grade infections occurred in 42% of sufferers; 15% had been grade 3 or increased. Hematologic unwanted effects included neutropenia (any grade, 38%; grade 3 or increased, 31%), thrombocytopenia (8%; 4%) and anemia (31%; 15%). Hypogammaglobulinemia occurred in 15% of sufferers.
In those that obtained KITE-363 at DL1 or DL2, grade 1 or 2 CRS occurred in 64% of sufferers and grade 3 ICANS occurred in 9%. The median time to onset of CRS was six days and the median period was three days. The median time to onset of ICANS was additionally 6sixdays and the median period was six days. CRS was managed with Actemra in 45% of sufferers and corticosteroids in 27%. ICANS was managed with corticosteroids in 9% and Kineret in 9%.
In those that obtained the agent at DL3, grade 1 (gentle) or 2 (reasonable) CRS occurred in 88% and grade 3 CRS occurred in 4%. The median time to onset was 3.5 days and the median period was 5 days. Most occasions had been managed with Actemra (88%), adopted by corticosteroids (65%) and Kineret (4%). Grade 1 or 2 ICANS was skilled by 38%; this impact was grade 3 for 8%. The median time to onset was six days and the median period was 4.5 days. These results had been largely managed with corticosteroids (38%) adopted by Kineret (15%).
Further Revelations and Take-Dwelling Message
“KITE-363 cell enlargement was dose dependent, with markedly sturdy enlargement noticed in DL3, showing higher than 3- to 5-fold increased than with Yescarta,” Dahiya stated. Publish-infusion peak ranges of serum analytes had been additionally linked with KITE-363 pharmacokinetics and diminished toxicity.
Because of these early outcomes, the sturdy CAR T-cell enlargement and the appropriate toxicity profile, the agent can be beneath growth for sufferers with autoimmune illness, Dahiya concluded.
For extra information on most cancers updates, analysis and training, don’t neglect to subscribe to CURE®’s newsletters right here.
